RxDoctor Payments Data

Tufal Khan, MD

Psychiatry · Ardmore, OKNPI 1033168596

Payments from drug & device makers

$319in general payments, 2019–2025

Across 17 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$61
  • AbbVie$51
  • Otsuka America Pharmaceutical, Inc.$47
  • Johnson & Johnson$42
  • E.r. Squibb & Sons, L.L.C.$42
  • Teva Pharmaceuticals USA, Inc.$29
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$27385%
  • Education$4715%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$319 in reported general payments places this provider in the 50th percentile of 328 psychiatry providers in Oklahoma.

See all psychiatry providers in Oklahoma

Medicare billing

Part B allowed, 2024
$4,871
Medicare patients
13
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate136$450,547
IngrezzaValbenazine Tosylate14$108,313
SpravatoEsketamine Hcl79$81,344
AristadaAripiprazole Lauroxil21$55,069
Abilify MaintenaAripiprazole19$54,787
VraylarCariprazine Hcl27$37,021
Paliperidone ErPaliperidone133$28,796
RexultiBrexpiprazole12$19,361
VivitrolNaltrexone Microspheres11$18,439
Aripiprazole90$8,809
TrintellixVortioxetine Hydrobromide15$7,468
FetzimaLevomilnacipran Hcl11$5,530
Clozapine58$5,202
Divalproex Sodium ErDivalproex Sodium67$4,480
Ziprasidone Hcl51$3,636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Spravato$42$531,891215 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$47$74,14831 claims
Alkermes, Inc.Aristada, Vivitrol$19$73,50832 claims
AbbVieVraylar, Fetzima$51$42,55038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 328 psychiatry providers in Oklahoma.

Other psychiatry in Ardmore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →